Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ContraFect Corporation (NASDAQ: CFRX).

Full DD Report for CFRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CFRX)

ContraFect Announces First Quarter 2018 Financial Results
YONKERS, N.Y. , May 10, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for t...
Source: GlobeNewswire
Date: May, 10 2018 07:00
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious ...
Source: PR Newswire
Date: April, 20 2018 10:17
ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pres...
Source: GlobeNewswire
Date: April, 11 2018 09:00
Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of ContraFect Corporation (NASDAQ: CFRX ) investors concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased ContraFect stock, have...
Source: Business Wire
Date: March, 27 2018 15:04
Free Post Earnings Research Report: Incyte's Quarterly Sales 36% Surged
Stock Monitor: ContraFect Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free earnings report on Incyte Corp. (NASDAQ: INCY ). If you want access to this report all you need to do is sign up now by clicking the following l...
Source: ACCESSWIRE IA
Date: March, 27 2018 07:00
Midday Gainers / Losers (3/16/2018)
Gainers: AMTX +152% . SEED +26% . CVRS +22% . IFMK +22% . TLGT +22% . QBAK +21% . SMRT +21% . ZSAN +21% . AMRS +20% . CTRN +15% . More news on: Aemetis, Inc., Origin Agritech Limited, Corindus Vascular Robotics, Inc., Stocks on the move, , Read more ......
Source: SeekingAlpha
Date: March, 16 2018 12:45
ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
YONKERS, N.Y., March 15, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for ...
Source: GlobeNewswire
Date: March, 15 2018 07:00
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that...
Source: GlobeNewswire
Date: March, 14 2018 07:00
ContraFect to Present at Cantor Antibiotics Summit
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Stev...
Source: GlobeNewswire
Date: January, 11 2018 07:00
ContraFect to Present at 10th Annual Biotech Showcase
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, P...
Source: GlobeNewswire
Date: January, 03 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-201.971.88381.971.88108,804
2018-08-172.001.952.00291.9079,768
2018-08-162.012.002.08651.99180,166
2018-08-152.011.992.011.9105108,919
2018-08-142.022.002.021.9183,863

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2016,58752,44631.6268Cover
2018-08-1721,74826,14883.1727Short
2018-08-1624,812112,99721.9581Cover
2018-08-1524,44049,26549.6093Short
2018-08-146,37337,50716.9915Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CFRX.


About ContraFect Corporation (NASDAQ: CFRX)

Logo for ContraFect Corporation (NASDAQ: CFRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CFRX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 21 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: March, 21 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 15 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: CFRX)

      Daily Technical Chart for (NASDAQ: CFRX)


      Stay tuned for daily updates and more on (NASDAQ: CFRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CFRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CFRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CFRX and does not buy, sell, or trade any shares of CFRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/